Related references
Note: Only part of the references are listed.Population Pharmacokinetics of Ceftolozane/Tazobactam in Healthy Volunteers, Subjects With Varying Degrees of Renal Function and Patients With Bacterial Infections
Gurudatt Chandorkar et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Activity of Ceftolozane-Tazobactam against a Broad Spectrum of Recent Clinical Anaerobic Isolates
David R. Snydman et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Mutation-Driven β-Lactam Resistance Mechanisms among Contemporary Ceftazidime-Nonsusceptible Pseudomonas aeruginosa Isolates from US Hospitals
Mariana Castanheira et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Impact of Renal Function on the Pharmacokinetics and Safety of Ceftolozane-Tazobactam
Myra Wooley et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Multicenter, Double-Blind, Randomized, Phase II Trial To Assess the Safety and Efficacy of Ceftolozane-Tazobactam plus Metronidazole Compared with Meropenem in Adult Patients with Complicated Intra-Abdominal Infections
Christopher Lucasti et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
In vivo efficacy of ceftolozane against Pseudomonas aeruginosa in a rabbit experimental model of pneumonia: Comparison with ceftazidime, piperacillin/tazobactam and imipenem
Cedric Bretonniere et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2014)
In Vivo Activities of Ceftolozane, a New Cephalosporin, with and without Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, Including Strains with Extended-Spectrum β-Lactamases, in the Thighs of Neutropenic Mice
W. A. Craig et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2011-2012)
David J. Farrell et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
10 x '20 Progress-Development of New Drugs Active Against Gram-Negative Bacilli: An Update From the Infectious Diseases Society of America
Helen W. Boucher et al.
CLINICAL INFECTIOUS DISEASES (2013)
Efficacy of ceftolozane in a murine model of Pseudomonas aeruginosa acute pneumonia: in vivo antimicrobial activity and impact on host inflammatory response
Cedric Jacqueline et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2013)
In Vivo Comparison of CXA-101 (FR264205) with and without Tazobactam versus Piperacillin-Tazobactam Using Human Simulated Exposures against Phenotypically Diverse Gram-Negative Organisms
Catharine C. Bulik et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Pan-β-Lactam Resistance Development in Pseudomonas aeruginosa Clinical Strains: Molecular Mechanisms, Penicillin-Binding Protein Profiles, and Binding Affinities
Bartolome Moya et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Pharmacokinetics and Safety of Intravenous Ceftolozane-Tazobactam in Healthy Adult Subjects following Single and Multiple Ascending Doses
Benjamin Miller et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects
Gurudatt Chandorkar et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
Antimicrobial Activity of CXA-101, a Novel Cephalosporin Tested in Combination with Tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis Strains Having Various Resistance Phenotypes
Helio S. Sader et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Combating Antimicrobial Resistance: Policy Recommendations to Save Lives
Robert J. Guidos et al.
CLINICAL INFECTIOUS DISEASES (2011)
Attributable Hospital Cost and Length of Stay Associated with Health Care-Associated Infections Caused by Antibiotic-Resistant Gram-Negative Bacteria
Patrick D. Mauldin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Activity of a New Cephalosporin, CXA-101 (FR264205), against β-Lactam-Resistant Pseudomonas aeruginosa Mutants Selected In Vitro and after Antipseudomonal Treatment of Intensive Care Unit Patients
Bartolome Moya et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Pharmacokinetics and Safety of CXA-101, a New Antipseudomonal Cephalosporin, in Healthy Adult Male and Female Subjects Receiving Single- and Multiple-Dose Intravenous Infusions
Yigong Ge et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients
L. Zamorano et al.
CLINICAL MICROBIOLOGY AND INFECTION (2010)
Progress and Challenges in Implementing the Research on ESKAPE Pathogens
Louis B. Rice
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2010)
Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus β-lactamase-producing Enterobacteriaceae
David M. Livermore et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Hospital and Societal Costs of Antimicrobial-Resistant Infections in a Chicago Teaching Hospital: Implications for Antibiotic Stewardship
Rebecca R. Roberts et al.
CLINICAL INFECTIOUS DISEASES (2009)
Structural requirements for the stability of novel cephalosporins to AmpC β-lactamase based on 3D-structure
Kenji Murano et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2008)
Synthesis and SAR of novel parenteral anti-pseudomonal cephalosporins: Discovery of FR264205
Ayako Toda et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
The epidemic of antibiotic-resistant infections: A call to action for the medical community from the Infectious Diseases Society of America
Brad Spellberg et al.
CLINICAL INFECTIOUS DISEASES (2008)
Pseudomonas aeruginosa:: resistance and therapeutic options at the turn of the new millennium
N. Mesaros et al.
CLINICAL MICROBIOLOGY AND INFECTION (2007)
In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa
Shinobu Takeda et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
The future should not look like the past
[Anonymous]
LANCET INFECTIOUS DISEASES (2006)
Antimicrobial resistance in the hospital setting: Impact, trends, and infection control measures
GE Stein
PHARMACOTHERAPY (2005)
Antipseudomonal antibiotics
H Giamarellou et al.
MEDICAL CLINICS OF NORTH AMERICA (2001)
Share Paper
